FIRST BLOCKCHAIN BIOTECH ECOSYSTEM
Be part of a company with a multi-billion dollar potential
What is the token functionality
- 10 tokens from the main sale event (0.000266 ETH — for 1 token, and 0.00266 ETH — for 10 tokens) can be used to purchase 1 ARNA BC test. Anticipated average market price of one ARNA BC test is 0.33333 ETH.
- Holders of large amounts of tokens will be eligible to participate in ARNA VIP Reward Program, offering unprecedented opportunity.
- ARNA tokens will be used on ARNA Panacea platform as cryptocurrency for payments between platform participants.
- Researchers will be able to conduct “crowdfunding” events on their breakthrough inventions in biotech.
- …and other use – read more in our White paper.
“I personally believe, like many other people, that the clinical trial system we have right now is broken. It isn’t working to meet the objectives that we need it for,” – Janet Woodcock, director of the Center for Drug Evaluation and Research at the Food and Drug Administration
Introducing ARNA Panacea
ARNA Panacea is a Biotech Decentralized Solution, Powered by Blockchain & ARNA Tokens
ARNA Panacea by design is a platform which allows not only processing of clinical trials data but also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients).
Your Chance to enter in Biotech Market
ARNA Genomics is the innovative biotechnological company engaged in R&D and launching on market methods of oncological diseases early detection using blockchain-ecosystem ARNA Panacea
ARNA BC is the first test developed product for early detection of breast cancer with a high-precision.
ARNA BC and Cancer Market Overview
to revolutionize the way disruptive biotech technologies aimed to fight cancer are launched to the mass-market with the use of Blockchain technologies
ARNA Panacea use cases
|Role of token:||
ARNA BC test purchase, ARNA Panacea data access, R&D rewarding
|Token Distribution Event:||
500 million (50%)
1 ARNA token = 0.000266 ETH
Token Distribution Event details:
19 november - 03 december
|Token distribution date:||
21 december 2017
3 333 ETH
|Maximum cap (approx.):||
130 000 ETH
|How funds are held:||
Wallet held by team
|Unsold tokens policy:||
Transferred into marketing budget
|Minimum viable product:||
More than 10 years ago started the project with mission to save lives from cancer. Economist and manager by education, entrepreneur by experience and spirit. Made several successful startups as founder and co-founder in advertising and production business, international logistics, IT solutions for large-scale projects, was CEO of international telecom operator. ARNA – is the meaning of Egor’s life.
Master of physics (diploma with honors), have 14 articles and inventions. Successfully worked in large international companies (Delloite, etc.), as well as in private equity companies. He has extensive experience as executive manager in various major private and public companies in IT, telecom, oil&gas.
Having more than 40 years of experience in molecular biology and genetics, he is the author and co-author of more than 50 scientific articles and number of patents. For 15 years he worked in the USA in oncological centers, before that – in Canada, Hungary in various scientific companies, and Russia – a branch of the Institute of Bioorganic Chemistry of the Russian Academy of Sciences and the Institute of Biochemistry and Physiology of Microorganisms of the Russian Academy of Sciences. He graduated from the biological faculty of the Lomonosov Moscow State University.
Development Manager for Scientific and Educational Programs (F. Paulsen Assisted Reproductive Technologies Center, Russian Ministry of Health). Former: medical advisor (MC Femina, Vitrolife), clinical embryologist (MD Medical Group), Jr. scientist (Wageningen University, The Netherlands)
Branch of the Institute of Bioorganic Chemistry Acad. M.M. Shemyakin and A. Ovchinnikov Institute of Sciences, Pushchino. Specialization — molecular biology, biotechnology, genetic engineering. Area of scientific expertise: regulation of gene expression, transcription, translation, molecular mechanisms of bacterial phage lysis.
Software architect and developer. Has a big experience working with start-ups in the areas of e-commerce, PR & Marketing, finance, transportation, ERP development. Mainly focused on building SaaS, APIs & complex business processes automation. Had been working in international companies in Russia, Ireland, and Germany.
Founder, CEO and Principal engineer in blockchain integrator Dicoiner (www.dicoiner.com) Founder and CEO in mobile development studio Zero Cool Team. 10 years experience in enterprise fintech software design and development. Last two yeast making research and implementation of blockchain systems. Graduate of IIDF-2015(Internet Initiatives Development Fund) in the team of Teslawatch startup.
15 scientific publications in the field of natural language processing
Entrepreneur and co-owner of several companies in the oilfield service, medicine and biotech. He graduated from the Faculty of Computational Mathematics and Cybernetics of the Moscow State University Lomonosov, EMBA Higher School of Economics, studied at the Skolkovo Management School, INSEAD and graduate school of MGIMO. He has extensive executive experience in oil&gas public and private companies.
has a master’s degree in physics. During his professional experience, he worked in various business areas, mainly focusing on the active development of the contractual base of enterprises. He has experience in working in a Western consulting company, a resort development company, a Swiss investment fund and a Russian exploration company.
Dmitry Kulish is an independent expert in the fields of strategic, organizational and technological development of pharmaceutical products. Dmitry holds a PhD in Biology, has been a postdoc at Harvard Medical School, earned MBA from the Wharton Business School, the Institute of Molecular Genetics of the Russian Academy of Sciences, and the Moscow State Institute of Molecular Biology Lomonosov Moscow State University.
Ph.D DR. Soenke Bartling
worked and lived in China since 1991. He has more than 20 years of experience in international management in China and Hong Kong. He held the positions of Chairman of the Board of Directors in various companies in China involved in international trade, investment and production. Since 2017, he was the General Manager of Sanju Environmental Protection (Hong Kong) Limited, coordinating the international projects of the controlling shareholder.
Dr. Alex Kоsik is a successful serial technology entrepreneur. His focus is in Life Sciences, Medical Devices, FDA Compliance, Evidence-Based Medicine, Venture Capital and M&A. Alex is a recognized technology due diligence expert and senior analyst to several VC’s, angels, Gerson Lehrman Group and institutional investors. He co-founded multiple businesses himself, met Bill Gates, sold his “G1 Gravitonus workstations” to Forbes-100, and ranked 3rd by Becker’s Spine Review of “10 spine orthopedic surgeon tech entrepreneurs to know”
Over 20 years of successful general management experience with a particular focus on business development and operational excellence. Сonstant over 5 years trend in business development and financial results improvement for large European integrated company with over 8 bln. USD in turnover and presence in over 15 countries. Has implemented several very successful business alliances strategies where the managed companies/clients have benefited from new distribution channels/partners reach.
Mikhail joined Atlant Clinical in 2012 as Chief Executive Officer and as a member of the Board of Directors. Prior to Atlant Clinical he worked at GlaxoSmithKline where he started as a clinical research assistant, later becoming a local study manager in the oncology group. He subsequently joined the Moscow Sales Department, where he rose to become Regional Market Access Director. Mikhail graduated from Lomonosov Moscow State University with Master degrees in biochemistry and management.
is a Doctor of Medical Sciences, a laureate of the Russian Government Prize in Science, a holder of post-doctoral degree in medicine of the Technical University of Munich, the Director of the Center for Personalized Oncology Sechenov OncoTarget, established as part of the Institute of Personalized Medicine in 2017
Ilya N. Chistyakov
MD., PhD, founder and CEO of the Preclinical Study Centre LLC, managing company of “Pharma Valley” biotechnological cluster – the only GLP OECD in Russia, an independent hybrid CRO specialized on conducting a full cycle of pharmacological development, manufacturing, preclinical and clinical studies of biotechnological, biosimilar and generic medicines.
has more than 20 years of experience in biotech investments and strategic consulting. Partner of venture fund “Maxwell Biotech” (Moscow), director of consulting company Candesic (London). Edward is an acting head of Investment Service of Skolkovo fund, vice-president of Investment Bank “Trust” and consultant of New Jersey office of McKinsey company. His career has started in Bill and Melinda Gates Foundation Fund. MBA from Harvard Business School, MD with PhD.
ARNA Genomics was established
Obtained status of a member of the Skolkovo biomedical cluster
Development of ARNA-Thermometr, a test for the presence of oncological diseases;
“Know-how” objects formalization
Development of ARNA Breast Cancer — a high-precision test for early detection of breast cancer
Development of ARNA Colon Cancer;
ARNA BC development is completed;
Beginning of laboratory tests of ARNA BC;
Submission of patent application No 1
End of laboratory tests of ARNA BC;
Start of ARNA BC clinical research jointly with Sechenov University;
Submission of application of Patent Cooperation Treaty No 1;
Token Distribution Event
Opening of the office and the 1st laboratory unit in the USA.
Submission of application of Patent Cooperation Treaty No 2 and 3.
Agreement of the regulatory strategy for ARNA BC. Launch of clinical research No 1 in the USA with FDA.
ARNA CC development is completed, starting laboratory research.
ARNA Panacea – launch of the beta version of blockchain-ecosystem, basic documentation for developers.
Using of ARNA Panacea’s blockchain ecosystem by interested market players (regulators, investors, users, etc.)
Start of development: ARNA Lung, ARNA Liver, ARNA Pancreas;
ARNA BC’s entry into the US market;
Clinical trials in China;
National phases: USA, China, India, EU, UK, Israel, Brazil;
Seed round B;
Receiving the first revenue.
Arna Genomics Introduces A Revolutionary Solution For Cancer Diagnostics And Treatment Biotechnologies – Blockchain Ecosystem Arna Panacea.
ARNA Panacea by design is platform which allows not only processing of clinical trials data but also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients)…READ MORE
ARNA Panacea — Blockchain Biotech Ecosystem
ARNA Genomics introduces a revolutionary solution for cancer diagnostics and treatment biotechnologies — blockchain-ecosystem ARNA Panacea.
ARNA Panacea by design is platform which allows not only processing of clinical trials data but also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients)… READ MORE
ARNA Genomics Develops Blockchain Powered Cancer Research Solution, Announces ICO
ABitcoin has not just revolutionized the global financial system, but it seems to be on its way to changing the healthcare industry as well. ARNA Genomics, a Russian biotechnology company, is demonstrating the potential of blockchain in healthcare with its ARNA Panacea platform… READ MORE